The research looks into detail at The Chinese National Reimbursement Drug List (NRDL) and reforms that have resulted in changes to the reimbursement process and how new drugs are launched within the market.
GPI attended and presented research at HTAi, held in Utrecht, Netherlands, 25-29 June 2022. GPI presented two research posters, including ‘List prices for Medicare negotiation-eligible medicines targeted by Build Back Better drug pricing provisions estimated to be reduced by over 40% on average‘. The research looks into detail at The Chinese National Reimbursement Drug List (NRDL) and reforms that have resulted in changes to the reimbursement process and how new drugs are launched within the market.
Background & Objective
The Chinese National Reimbursement Drug List (NRDL) was founded in the early 2000’s. Since its establishment, the health system in China has undergone reforms that have resulted in changes to the reimbursement process and how new drugs are launched within the market. It is important for manufacturers to understand how such changes impact access opportunities in China. In this HTAi poster, we would like to evaluate the evolving price and reimbursement landscape in China and understand the perspectives of payers and policy experts within the field, using both secondary and primary research.
Research Details
Conference: HTAi Annual Meeting
Focus Topics: Chinese National Reimbursement Drug List, NRDL, Drug Pricing, Market ccess
Resources: GPI pulse™ Data Analytics Platform, GPI consulting, Price & Market Access Specialists
Find out more about GPI
This research, and all of our research, utilise data from our analytics platform, GPI pulse™.
Share this research:
Importance of time horizon and analogue selection for value-based pricing of cell and gene therapies
